The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer's disease

Neurobiology of Aging

Volumn 33, Issue 8, 2012, Pages 1651-1663

  Kalinin, Sergey ^a   Polak, Paul E ^a   Lin, Shao Xia ^a   Sakharkar, Amul J ^a,b   Pandey, Subhash C ^a,b   Feinstein, Douglas L ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

Droxidopa; GFAP; Glial cells; Inflammation; Learning and memory; Locus coeruleus; Morris water maze; Neprilysin; Neurotrophin; Noradrenaline; Thioflavin S; Tyrosine hydroxylase

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; INSULINASE; MEMBRANE METALLOENDOPEPTIDASE; MESSENGER RNA; NEUROTROPHIN; NORADRENALIN; THREO 3,4 DIHYDROXYPHENYLSERINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL ACTIVATION; CELL STRESS; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; LATENT PERIOD; MALE; MAZE TEST; MOUSE; NONHUMAN; NORADRENALIN BRAIN LEVEL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADRENERGIC NEURONS; ALZHEIMER DISEASE; ANIMALS; ANTIPARKINSON AGENTS; DROXIDOPA; LOCUS COERULEUS; MALE; MAZE LEARNING; MICE; MICE, TRANSGENIC; NOREPINEPHRINE; TREATMENT OUTCOME;

EID: 84861878510     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2011.04.012     Document Type: Article

References (60)

1. Adolfsson R., Gottfries C.G., Roos B.E., Winblad B. Changes in the brain catecholamines in patients with dementia of Alzheimer type. Br. J. Psychiatry 1979, 135:216-223.
2. Arenas E., Persson H. Neurotrophin-3 prevents the death of adult central noradrenergic neurons in vivo. Nature 1994, 367:368-371.
3. Benveniste E.N., Huneycutt B.S., Shrikant P., Ballestas M.E. Second messenger systems in the regulation of cytokines and adhesion molecules in the central nervous system. Brain Behav. Immun 1995, 9:304-314.
4. Bondareff W., Mountjoy C.Q., Roth M., Rossor M.N., Iversen L.L., Reynolds G.P., Hauser D.L. Neuronal degeneration in locus ceruleus and cortical correlates of Alzheimer disease. Alzheimer Dis. Assoc. Disord 1987, 1:256-262.
5. Chan-Palay V. Alterations in the locus coeruleus in dementias of Alzheimer's and Parkinson's disease. Prog. Brain Res 1991, 88:625-630.
6. Cole G.M., Frautschy S.A. Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease. CNS Neurol. Disord. Drug Targets 2010, 9:140-148.
7. Counts S.E., Mufson E.J. Noradrenaline activation of neurotrophic pathways protects against neuronal amyloid toxicity. J. Neurochem 2010, 113:649-660.
8. Fawcett J.P., Bamji S.X., Causing C.G., Aloyz R., Ase A.R., Reader T.A., McLean J.H., Miller F.D. Functional evidence that BDNF is an anterograde neuronal trophic factor in the CNS. J. Neurosci 1998, 18:2808-2821.
9. Feinstein D.L., Galea E., Reis D.J. Norepinephrine suppresses inducible nitric oxide synthase activity in rat astroglial cultures. J. Neurochem 1993, 60:1945-1948.
10. German D.C., Manaye K.F., White C.L., Woodward D.J., McIntire D.D., Smith W.K., Kalaria R.N., Mann D.M. Disease-specific patterns of locus coeruleus cell loss. Ann. Neurol 1992, 32:667-676.
11. German D.C., Nelson O., Liang F., Liang C.L., Games D. The PDAPP mouse model of Alzheimer's disease: locus coeruleus neuronal shrinkage. J. Comp. Neurol 2005, 492:469-476.
12. Goldstein D.S. L-Dihydroxyphenylserine (L-DOPS): a norepinephrine prodrug. Cardiovasc. Drug Rev 2006, 24:189-203.
13. Guérin D., Sacquet J., Mandairon N., Jourdan F., Didier A. Early locus coeruleus degeneration and olfactory dysfunctions in Tg2576 mice. Neurobiol. Aging 2009, 30:272-283.
14. Heneka M.T., Galea E., Gavriluyk V., Dumitrescu-Ozimek L., Daeschner J., O'Banion M.K., Weinberg G., Klockgether T., Feinstein D.L. Noradrenergic depletion potentiates beta -amyloid-induced cortical inflammation: implications for Alzheimer's disease. J. Neurosci 2002, 22:2434-2442.
15. Heneka M.T., Nadrigny F., Regen T., Martinez-Hernandez A., Dumitrescu-Ozimek L., Terwel D., Jardanhazi-Kurutz D., Walter J., Kirchhoff F., Hanisch U.K., Kummer M.P. Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:6058-6063.
16. Heneka M.T., O'Banion M.K. Inflammatory processes in Alzheimer's disease. J. Neuroimmunol 2007, 184:69-91.
17. Heneka M.T., Ramanathan M., Jacobs A.H., Dumitrescu-Ozimek L., Bilkei-Gorzo A., Debeir T., Sastre M., Galldiks N., Zimmer A., Hoehn M., Heiss W.D., Klockgether T., Staufenbiel M. Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J. Neurosci 2006, 26:1343-1354.
18. Holm P.C., Rodriguez F.J., Kresse A., Canals J.M., Silos-Santiago I., Arenas E. Crucial role of TrkB ligands in the survival and phenotypic differentiation of developing locus coeruleus noradrenergic neurons. Development 2003, 130:3535-3545.
19. Holm P.C., Rodriguez F.J., Kresse A., Canals J.M., Silos-Santiago I., Arenas E. Crucial role of TrkB ligands in the survival and phenotypic differentiation of developing locus coeruleus noradrenergic neurons. Development 2003, 130:3535-3545.
20. Hoogendijk W.J., Pool C.W., Troost D., van Zwieten E., Swaab D.F. Image analyser-assisted morphometry of the locus coeruleus in Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. Brain 1995, 118:131-143.
21. Jardanhazi-Kurutz D., Kummer M.P., Terwel D., Vogel K., Dyrks T., Thiele A., Heneka M.T. Induced LC degeneration in APP/PS1 transgenic mice accelerates early cerebral amyloidosis and cognitive deficits. Neurochem. Int 2010, 57:375-382.
22. Kalinin S., Gavrilyuk V., Polak P.E., Vasser R., Zhao J., Heneka M.T., Feinstein D.L. Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimer's disease. Neurobiol. Aging 2007, 28:1206-1214.
23. Kalinin S., Polak P.E., Madrigal J.L., Gavrilyuk V., Sharp A., Chauhan N., Marien M., Colpaert F., Feinstein D.L. Beta-amyloid-dependent expression of NOS2 in neurons: prevention by an alpha2-adrenergic antagonist. Antioxid. Redox Signal 2006, 8:873-883.
24. Kimura R., Devi L., Ohno M. Partial reduction of BACE1 improves synaptic plasticity, recent and remote memories in Alzheimer's disease transgenic mice. J. Neurochem 2010, 113:248-261.
25. Liu Y., Yoo M.J., Savonenko A., Stirling W., Price D.L., Borchelt D.R., Mamounas L., Lyons W.E., Blue M.E., Lee M.K. Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer's disease. J. Neurosci 2008, 28:13805-13814.
26. Madrigal J.L., Kalinin S., Richardson J.C., Feinstein D.L. Neuroprotective actions of noradrenaline: effects on glutathione synthesis and activation of peroxisome proliferator activated receptor delta. J. Neurochem 2007, 103:2092-2101.
27. Madrigal J.L., Russo C.D., Gavrilyuk V., Feinstein D.L. Effects of noradrenaline on neuronal NOS2 expression and viability. Antioxid. Redox Signal 2006, 8:885-892.
28. Mann D.M. The locus coeruleus and its possible role in ageing and degenerative disease of the human central nervous system. Mech. Ageing Dev 1983, 23:73-94.
29. Marien M.R., Colpaert F.C., Rosenquist A.C. Noradrenergic mechanisms in neurodegenerative diseases: a theory. Brain Res. Brain Res. Rev 2004, 45:38-78.
30. Minichiello L. TrkB signalling pathways in LTP and learning. Nat. Rev. Neurosci 2009, 10:850-860.
31. Mohs R.C., Shiovitz T.M., Tariot P.N., Porsteinsson A.P., Baker K.D., Feldman P.D. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study. Am. J. Geriatr. Psychiatry 2009, 17:752-759.
32. O'Neil J.N., Mouton P.R., Tizabi Y., Ottinger M.A., Lei D.L., Ingram D.K., Manaye K.F. Catecholaminergic neuronal loss in locus coeruleus of aged female dtg APP/PS1 mice. J. Chem. Neuroanat 2007, 34:102-107.
33. O'Sullivan J.B., Ryan K.M., Harkin A., Connor T.J. Noradrenaline reuptake inhibitors inhibit expression of chemokines IP-10 and RANTES and cell adhesion molecules VCAM-1 and ICAM-1 in the CNS following a systemic inflammatory challenge. J. Neuroimmunol 2010, 220:34-42.
34. Oakley H., Cole S.L., Logan S., Maus E., Shao P., Craft J., Guillozet-Bongaarts A., Ohno M., Disterhoft J., Van E.L., Berry R., Vassar R. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci 2006, 26:10129-10140.
35. Ohno M., Chang L., Tseng W., Oakley H., Citron M., Klein W.L., Vassar R., Disterhoft J.F. Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1. Eur. J. Neurosci 2006, 23:251-260.
36. Palmer A.M., DeKosky S.T. Monoamine neurons in aging and Alzheimer's disease. J. Neural Transm. Gen. Sect 1993, 91:135-159.
37. Paxinos G., Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates 2001, Academic Press, San Diego. second ed.
38. Peng S., Wuu J., Mufson E.J., Fahnestock M. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. J. Neurochem 2005, 93:1412-1421.
39. Peskind E.R., Tsuang D.W., Bonner L.T., Pascualy M., Riekse R.G., Snowden M.B., Thomas R., Raskind M.A. Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: a placebo-controlled study. Alzheimer Dis. Assoc. Disord 2005, 19:23-28.
40. Prakash A., Zhang H., Pandey S.C. Innate differences in the expression of brain-derived neurotrophic factor in the regions within the extended amygdala between alcohol preferring and nonpreferring rats. Alcohol. Clin. Exp. Res 2008, 32:909-920.
41. Pugh P.L., Vidgeon-Hart M.P., Ashmeade T., Culbert A.A., Seymour Z., Perren M.J., Joyce F., Bate S.T., Babin A., Virley D.J., Richardson J.C., Upton N., Sunter D. Repeated administration of the noradrenergic neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) modulates neuroinflammation and amyloid plaque load in mice bearing amyloid precursor protein and presenilin-1 mutant transgenes. J. Neuroinflammation 2007, 4:8.
42. Rangasamy S.B., Soderstrom K., Bakay R.A., Kordower J.H. Neurotrophic factor therapy for Parkinson's disease. Prog. Brain Res 2010, 184:237-264.
43. Rémy S., Naveilhan P., Brachet P., Neveu I. Differential regulation of GDNF, neurturin, and their receptors in primary cultures of rat glial cells. J. Neurosci. Res 2001, 64:242-251.
44. Salehi A., Faizi M., Colas D., Valletta J., Laguna J., Takimoto-Kimura R., Kleschevnikov A., Wagner S.L., Aisen P., Shamloo M., Mobley W.C. Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome. Sci. Transl. Med 2009, 1:7ra17.
45. Samuels E.R., Szabadi E. Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans. Curr. Neuropharmacol 2008, 6:254-285.
46. Sara S.J. The locus coeruleus and noradrenergic modulation of cognition. Nat. Rev. Neurosci 2009, 10:211-223.
47. Sastre M., Walter J., Gentleman S.M. Interactions between APP secretases and inflammatory mediators. J. Neuroinflammation 2008, 5:25.
48. Scullion G.A., Kendall D.A., Marsden C.A., Sunter D., Pardon M.C. Chronic treatment with the α(2)-adrenoceptor antagonist fluparoxan prevents age-related deficits in spatial working memory in APP×PS1 transgenic mice without altering β-amyloid plaque load or astrocytosis. Neuropharmacology 2011, 60:223-234.
49. Simonini M.V., Polak P.E., Sharp A., McGuire S., Galea E., Feinstein D.L. Increasing CNS noradrenaline reduces EAE severity. J. Neuroimmune. Pharmacol 2010, 5:252-259.
50. Szabó C., Haskó G., Zingarelli B., Németh Z.H., Salzman A.L., Kvetan V., Pastores S.M., Vizi E.S. Isoproterenol regulates tumour necrosis factor, interleukin-10, interleukin-6 and nitric oxide production and protects against the development of vascular hyporeactivity in endotoxaemia. Immunology 1997, 90:95-100.
51. Szapacs M.E., Numis A.L., Andrews A.M. Late onset loss of hippocampal 5-HT and NE is accompanied by increases in BDNF protein expression in mice co-expressing mutant APP and PS1. Neurobiol. Dis 2004, 16:572-580.
52. Szekely C.A., Zandi P.P. Non-steroidal anti-inflammatory drugs and Alzheimer's disease: the epidemiological evidence. CNS Neurol. Disord. Drug Targets 2010, 9:132-139.
53. Szot P., White S.S., Greenup J.L., Leverenz J.B., Peskind E.R., Raskind M.A. Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies. J. Neurosci 2006, 26:467-478.
54. Szot P., White S.S., Greenup J.L., Leverenz J.B., Peskind E.R., Raskind M.A. Changes in adrenoreceptors in the prefrontal cortex of subjects with dementia: evidence of compensatory changes. Neuroscience 2007, 146:471-480.
55. Traver S., Marien M., Martin E., Hirsch E.C., Michel P.P. The phenotypic differentiation of locus ceruleus noradrenergic neurons mediated by brain-derived neurotrophic factor is enhanced by corticotropin releasing factor through the activation of a cAMP-dependent signaling pathway. Mol. Pharmacol 2006, 70:30-40.
56. Tsien J.Z., Huerta P.T., Tonegawa S. The essential role of hippocampal CA1 NMDA receptor-dependent synaptic plasticity in spatial memory. Cell 1996, 87:1327-1338.
57. Urano T., Tohda C. Icariin improves memory impairment in Alzheimer's disease model mice (5xFAD) and attenuates amyloid β-induced neurite atrophy. Phytother. Res 2010, 24:1658-1663.
58. Wang L.Y., Shofer J.B., Rohde K., Hart K.L., Hoff D.J., McFall Y.H., Raskind M.A., Peskind E.R. Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. Am. J. Geriatr. Psychiatry 2009, 17:744-751.
59. Weinshenker D. Functional consequences of locus coeruleus degeneration in Alzheimer's disease. Curr. Alzheimer Res 2008, 5:342-345.
60. Zarow C., Lyness S.A., Mortimer J.A., Chui H.C. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch. Neurol 2003, 60:337-341.